NCT04267601View on ClinicalTrials.gov

Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM

UnknownOBSERVATIONAL

Enrollment

2,448

Participants

Timeline

Start Date

July 6, 2017

Primary Completion Date

March 30, 2021

Study Completion Date

September 30, 2021

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Anagliptin

Anagliptin treatment for 24weeks

Trial Locations (1)

14647

The Catholic University of Korea, Bucheon ST. Mary's hopsital, Bucheon-si

Sponsors

Lead Sponsor

JW Pharmaceutical

All Listed Sponsors

lead

JW Pharmaceutical

INDUSTRY

NCT04267601 - Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM | Biotech Hunter | Biotech Hunter